Recombinant ADAMTS13 therapy just @US_FDA approved - will save these patients recurrent plasma infusions (every couple of weeks for months), a big win. https://t.co/lKdWTMp2oc #ACR23 Review Course @RheumNow https://t.co/2NMbJvseiA